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surgical and anesthesiology techniques, patients with
significant preoperative risk factors are at increased risk
of dying or having complications after CABG. The
major cause of complications during CABG is related
to the use of cardiopulmonary bypass (CPB) and car-
dioplegia,3 which in turn may lead to perioperative
myocardial infarction in 5% to 10% of patients.
Furthermore, hemodilution, reduced mean perfusion
pressure to the brain during CPB,4 cannulation, and
clamping and manipulation of the aorta required for
construction of proximal anastomoses expose patients
to the risk of stroke.5
Minimally invasive CABG (MICABG) through a
minithoracotomy without CPB recently has been intro-
duced successfully into clinical practice.6 We7 and oth-
ers8 have demonstrated decreased resource use and
improved results of MICABG compared with standard
CABG. On the basis of these results, we hypothesized
T he success and aggressive application of percuta-neous coronary revascularization techniques1 has
contributed at least in part to the increase of the mean
age and risk profile for patients referred for coronary
artery bypass grafting (CABG).2 Despite refinement of
Objective: Available risk assessment models are designed for standard
coronary artery bypass grafting. We hypothesized that minimally inva-
sive coronary bypass could improve on predicted outcome in extremely
high-risk patients (Parsonnet score > 20%) by the current risk models.
Methods: From September 1996 to September 1997, 27 consecutive
extremely high-risk patients underwent minimally invasive coronary
bypass. Seventeen patients were male; age was 73 ± 12 years, and 63%
of patients were older than 75 years. Left ventricular ejection fraction
was 33.7% ± 15% and 63% had an ejection fraction of less than 35%.
The predicted 30-day mortality according to the System 97 model was
25.6% ± 11.3%. The Parsonnet risk score was 36.2% ± 11%; the pre-
dicted length of stay in the hospital was 15.3 ± 3 days. The predicted risk
of stroke according to the Multicenter Perioperative Stroke Risk Index
was 22.3% ± 11.7%. Results: Minimally invasive coronary bypass was
isolated in 20 patients and integrated with angioplasty and stenting in 7
patients. The observed 30-day mortality was 0% (P < .01 vs predicted):
at an average follow-up of 10.8 ± 4.1 months, 26 patients (96.3%) are
alive without angina; one patient with acquired immunodeficiency syn-
drome died on postoperative day 40 of acute pancreatitis. No patient had
a stroke or neurologic deficit (P < .01 vs predicted). Patency of internal
thoracic artery anastomosis was confirmed by angiography in all 27
patients. No patient required reoperation. Eighteen patients (67%) were
extubated in the operating room. The observed length of hospital stay
after minimally invasive coronary bypass was 3.8 ± 2.6 days (P < .01 vs
predicted). Conclusion: On the basis of our results on a relatively small
series of patients, we suggest that risk models geared for standard coro-
nary bypass grafting may not be appropriate for minimally invasive
coronary bypass. (J Thorac Cardiovasc Surg 1998;116:584-9)
Marco Zenati, MD
Howard A. Cohen, MD
Richard Holubkov, PhD
A. J. Conrad Smith, MD
Arthur J. Boujoukos, MD
John Caldwell, MD
Leonard Firestone, MD
Bartley P. Griffith, MD
PREOPERATIVE RISK MODELS FOR MINIMALLY INVASIVE CORONARY BYPASS: A PRELIMINARY
STUDY
From the Divisions of Cardiothoracic Surgery, Cardiology, Critical
Care Medicine, and Anesthesiology, University of Pittsburgh
Medical Center, Pittsburgh, Pa.
Presented in part at the Seventieth Scientific Sessions of the
American Heart Association, Orlando, Fla, Nov 9-12, 1997.
Received for publication March 3, 1998; revisions requested May
26, 1998; revisions received June 23, 1998; accepted for publi-
cation June 24, 1998.
Address for reprints: Marco Zenati, MD, Division of Cardiothoracic
Surgery, University of Pittsburgh Medical Center, 200 Lothrop
St, Suite C-700, Pittsburgh PA 15213-2582.
Copyright © 1998 by Mosby, Inc.
0022-5223/98 $5.00 + 0 12/1/92807
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 4
Zenati et al   585
that MICABG, perhaps by avoiding CPB, could im-
prove results in patients in whom CABG is a high-risk
procedure. Inasmuch as the available risk assessment
models are designed for standard CABG, we also
hypothesized that these models would not be able to
accurately predict the outcome when MICABG was
performed instead of the standard CABG.
Methods
Patient population. From September 1996 to September
1997, 108 MICABG procedures were performed at the
University of Pittsburgh MeGoiter 1dical Center by 2
surgeons (M.Z. and B.P.G.). Among these 108 patients, 27
(25%) had a Parsonnet risk score9 greater than 20%: these
consecutive 27 “extremely high-risk”10 patients are the focus
of the present observational study.
Patient demographics are listed in Table I and risk factors
present in these patients (not mutually exclusive) are listed in
Table II. Twenty patients (20/27, 74%) had been turned down
as candidates for standard CABG by 1 or more surgeons
because of anticipated prohibitive risk. The remaining 7
patients were never referred for conventional CABG by the
cardiologist and would have been deemed to be candidates
for medical therapy if MICABG were not available. All
patients were in Canadian Cardiovascular Society angina
class III or greater or had objective evidence of ischemia.
Risk assessment models and definitions. The risks that
were assessed were (1) 30-day mortality; (2) perioperative
stroke; and (3) prolonged hospital stay after the procedure.
The risk of dying (30-day mortality) after CABG was cal-
culated with the use of the “System 97”11: this model, unlike
other models currently used, has been shown to approximate
the observed mortality after CABG extremely well and
recently has been extensively validated (Bernstein AD, per-
sonal communication, December 10, 1997).
The risk of prolonged hospital stay after CABG was calcu-
lated by means of a regression equation based on the
Parsonnet score.2 The correlation coefficient between ob-
served length of stay after CABG and the Parsonnet score is
very high (r = 0.976). Length of hospital stay is also a good
predictor of complication rate and of resource use.7
The risk of perioperative stroke was calculated by the
Multicenter Perioperative Stroke Index (McSPI).12 The
McSPI has been validated from a population of 2107 patients
by the use of the bootstrap technique, a valuable method for
validating predictive scales. The predicted risks of 30-day
mortality, prolonged hospital stay, and perioperative stroke
for the 27 patients are listed in Table III.
Multivessel coronary artery disease was defined as greater
than 70% luminal narrowing in the distribution of more than 1
major coronary artery (eg, left anterior descending [LAD],
right coronary artery, or circumflex. The goal of revasculariza-
tion was not to obtain necessarily a “complete” revasculariza-
tion, but rather a “functionally adequate” one.13 Functionally
adequate revascularization was defined as revascularization of
all stenoses of more than 70% in vessels with a diameter
greater than 1.5 mm that served viable myocardium. Vessels
serving infarcted ventricular territory, as demonstrated by
either akinesis on the ventriculogram or fixed perfusion defects
on thallium myocardial scintigraphy, were not considered
functionally important. For stenoses in the intermediate range
of severity (40%-60% luminal narrowing),14 revascularization
was undertaken only if stress thallium15 or coronary flow
reserve studies16 showed evidence of flow limitation.
Surgical technique. MICABG was performed through a 3-
inch minithoracotomy in the fourth or fifth intercostal space
under direct vision of the surgeon, without removal of any
costal cartilage or rib. Anesthesia was induced with propofol
(2-3 mg/kg) and maintained with modest doses of fentanyl
(15-25 m g/kg) and rocuronium (0.4 mg/kg). Intravenous infu-
sion of diltiazem (3-5 mg/h), as an ischemic preconditioning
agent, was used in all patients. A left-sided double-lumen
endotracheal tube was used in all cases to facilitate left inter-
Table I. Baseline clinical characteristics in 27 patients
Age (y) 73 ± 12
Age > 75 y (%) 63
Sex (%)
Female 37
Male 63
LVEF (%) 33.7 ± 15
Unstable angina (%) 85
Prior CABG (%) 7.4
No. of diseased vessels
One (%) 4
Two (%) 33
Three (%) 33
Left main (%) 30
LVEF, Left ventricular ejection fraction; CABG, coronary artery bypass graft.
Table II. Risk factors (not mutually exclusive)
Risk factor Percent of patients
CHF 67
Severe PVD 63
Severe COPD 70
Renal dysfunction 55
Age > 75 y 63
LVEF < 35(%) 63
Previous CVA 74
CHF, Congestive heart failure; PVD, peripheral vascular disease; COPD,
chronic obstructive pulmonary disease; LVEF, left ventricular ejection
fraction; CVA, cerebrovascular accident.
Table III. Predicted versus observed risks
Predicted Observed P value
Mortality (%) 25.6 ± 11.3 0 <.001
Stroke (%) 22.3 ± 11.7 0 <.001
LOS (d) 15.3 ± 3 3.9 ± 3.5 <.001
LOS, Length of hospital stay. 
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nal thoracic artery (LITA) harvest circumferentially as a pedi-
cle for its entire length from the subclavian artery takeoff to
the bifurcation (average length of LITA pedicle = 15 cm). A
dedicated LITA retractor (CardioThoracic Systems Inc,
Cupertino, Calif) was successfully used and provided excel-
lent exposure of the entire bed of the LITA. The heparin dose
used was 100 IU/kg. After division of the distal LITA, a 1/4-
force atraumatic bulldog vascular occluder (Applied Medical,
Laguna Hills, Calif) was used to interrupt LITA flow. The
LITA-LAD anastomosis was performed with a mechanical
stabilizer (CardioThoracic Systems) without harmful phar-
macologic manipulation of the heart rate17; the average heart
rate during the anastomosis was 72 beats/min. The LITA-
LAD anastomosis was performed with 2 separate 8-0 poly-
propylene sutures at the heel and toe (double-parachute tech-
nique) with a 6.5-mm needle with the help of a carbon
dioxide blower used very sparingly and set at a flow not higher
than 5 L/min to avoid damage to the coronary endothelium.
Before final tying of the suture, the anastomosis was probed
with a nonocclusive 1-mm Parsonnet probe in 3 directions:
proximal LAD, distal LAD, and proximal LITA; furthermore,
the LITA was flushed through the open suture line before
final tying of the knot to eliminate the potential for thrombus
formation at the site of application of the vascular occluder.
On completion of the anastomosis, the flow pattern of the
LITA was immediately analyzed with a customized ultra-
sound transit-time flowmeter (Transonic Systems Inc, Ithaca,
NY) as previously described by us.18 Extubation was attempt-
ed in all cases in the operating room. Postoperative pain con-
trol was achieved by a preoperatively placed epidural catheter
or by intercostal nerve block when an epidural catheter was
contraindicated (eg, with intravenous heparin infusion). In
patients with normal renal function, an age-adjusted bolus of
ketorolac was administered intravenously before reversal of
neuromuscular blockade. Compared with more routine
MICABG, when dealing with high-risk patients we are espe-
cially careful to avoid even brief episodes of hypotension;
thus a mean arterial pressure greater than 80 mm Hg is actively
maintained by means of phenylephrine and volume infusions.
Furthermore, arterial oxygen saturation is maintained higher
than 95% and manipulation of heart rate is avoided. LITA-
LAD anastomotic patency was confirmed angiographically in
all 27 patients within 48 hours of MICABG. Our MICABG
follow-up protocol included exercise or pharmacologic stress
thallium myocardial scintigraphy, Doppler echocardiography
of LITA flow,19 and physical examination at 1 month. 
Statistical analysis. Data were expressed as mean ± stan-
dard deviation. Comparison between predicted and observed
length of stay in the hospital was performed by means of the
sign test. For comparison of observed and predicted number
of events, the P value was computed by means of a permuta-
tion test, that is, the probability of observing no events in the
study population given each patient’s predicted probability of
the event. We note here and in the discussion that the pre-
dicted probabilities of events have an inherent variability that
is relatively high. Although the comparisons remained signifi-
cant under robustness calculations using the lower 95% con-
fidence limit for each patient’s estimate as the predicted
value, the P values reported are nevertheless approximate.
The protocol for MICABG and integrated coronary revas-
cularization was approved by the Institutional Review Board
of the University of Pittsburgh, and informed consent was
obtained from all patients.
Results
Characteristics of the operations performed are listed
in Table IV. In 7 patients (7/25, 28%), MICABG was
integrated with percutaneous coronary revascularization
of non-LAD coronary arteries in the cardiac catheteri-
zation laboratory.20,21 Details of MICABG and integrat-
ed coronary revascularization strategy are listed in Table
IV. All patients in whom a stent was used in conjunction
with integrated coronary revascularization received
aspirin and ticlopidine (250 mg by mouth twice a day)
for 1 month after revascularization. All patients sur-
vived MICABG (30-day mortality = 0): at a mean fol-
low-up of 10.8 ± 4.1 months, the survival is 96.3% (1
patient with acquired immunodeficiency syndrome died
on postoperative day 40 of acute pancreatitis).
The predicted 30-day mortality for this cohort of
patients according to the System 9711 was 25.6% ±
11.3% (P < .01 vs observed; Table III).
Three patients (11%) had postoperative atrial fibrilla-
tion. One patient required reintubation on postoperative
day 2 for bradycardia ( b -blocker overdose). One
patient had temporary worsening of renal dysfunction
(creatinine level rose from 2.0 to 3.3 mg/dL) after inte-
grated coronary revascularization with the use of con-
trast material. One patient was readmitted to the hospi-
tal on postoperative day 15 for upper gastrointestinal
Table IV. Revascularization strategy
Isolated MICABG 20 patients (74%)
Integrated MICABG/PTCA 7 patients (26%)
Same day 5 patients (5/7, 71%)*
POD 1 or 2 2 patients
Stent 4 patients
PTCA only 3 patients
Site
LMCA 1 patient
Circumflex 4 patients
Diagonal 1 patient
RCA 1 patient
MICABG LITA-LAD 27 patients
Anastomosis time 14 ± 2.3 min
Operation time (skin-to-skin) 122.6 ± 28 min
Extubation in OR 18 patients (67%)
MICABG, Minimally invasive coronary artery bypass; PTCA, percutaneous
transluminal coronary angioplasty; POD, postoperative day; LMCA, left main
coronary artery; RCA, right coronary artery; LITA, left internal thoracic artery;
LAD, left anterior descending coronary artery; OR, operating room.
*If left main coronary stenosis, MICABG was always performed first.
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tract bleeding that was treated conservatively. Another
patient, in whom a 95% stenosis of the proximal sub-
clavian artery was detected before MICABG, under-
went successful stent placement with reduction of the
stenosis from 95% to 5% and subsequently underwent
successful MICABG.
In another patient with severe peripheral vascular dis-
ease, a total occlusion of the proximal subclavian artery
was detected after MICABG at the time of the control
LITA angiogram; interestingly, this patient did not have
any blood pressure gradient between the right and left
arm before the operation, most likely because of com-
pensatory circulation from a large patent vertebral
artery. This patient underwent successful carotid-sub-
clavian bypass on postoperative day 2 after MICABG to
prevent a future steal phenomenon and was discharged
home on postoperative day 4.
LITA-LAD patency was confirmed in all 27 patients
(27/27, 100%) by contrast angiography. Patency was
also confirmed by intraoperative transit-time flowmetry
and postoperative Doppler flow study. The postproce-
dure hospital stay was 3.9 ± 3.5 days (range 2-16 days),
compared with a predicted hospital stay based on the
Parsonnet score of 15.3 ± 3 days (P < .01 vs predicted)
(Table III and Fig 1). No patient had a postoperative
stroke or major neurologic event after the procedure
(stroke incidence = 0%), compared with a predicted
risk of stroke according to the McSPI of 22.3% ±
11.7% (P < .01 vs predicted). At a mean follow-up of
10.8 ± 4.1 months, all 26 surviving patients are free of
recurrent angina and myocardial infarction.
Discussion
The risk profile of patients being referred for surgical
coronary revascularization has been steadily increasing
in severity during this decade.2 Recent studies suggest
that elderly patients with greater comorbidities and
advanced cardiovascular disease benefit more from
cardiac surgery than from medical therapy,22,23 yet they
paradoxically have greater morbidity and mortality
after cardiac surgery.24,25 Despite the 30 years that have
elapsed since the first CABG was performed by
Favaloro in 1967, and myriad subsequent refinements
in technique, major complications continue to be asso-
ciated with CABG, resulting in prolonged hospitaliza-
tions and resource use. Because the majority of com-
plications after CABG are related to the use of CPB, a
revascularization strategy that eliminates CPB would
seem a logical solution, especially in high-risk patients,
provided that equivalent effectiveness can be demon-
strated. MICABG provides such an alternative,
although it is limited in its scope to the anterolateral
left ventricular coronary distribution (LAD, diagonal,
ramus intermedius).26 To provide a “functionally ade-
quate” revascularization13 for patients with multivessel
coronary artery disease, we have previously described
an approach that we called “integrated coronary revas-
cularization,” which combines MICABG LITA-LAD
with angioplasty of non-LAD coronary lesions.20
We hypothesized that a coronary revascularization
strategy that eliminates CPB, such as isolated or inte-
grated MICABG, would yield superior results in high-
risk patients compared with those of standard CABG.
We used the Parsonnet risk score 9 to screen a consecu-
tive group of patients who received MICABG at our
institution during a 12-month period; 27 patients with a
Parsonnet score greater than 20% were identified.
Ideally, a randomized study design would be best to
assess the relative merits of standard CABG and
MICABG in this “extremely high-risk”10 cohort.
Unfortunately, 74% of patients in our group had been
turned down as candidates for standard CABG by 1 or
more surgeons because of anticipated prohibitive risk;
the remaining 7 patients were never referred for con-
Fig 1. Length of stay, observed versus predicted.
ventional CABG by the cardiologist. Therefore we
decided to test the observed outcome after MICABG
against the best risk assessment models available for
these patients. The outcomes assessed were 30-day
mortality, prolonged hospital stay (and resource use),
and stroke.
We observed no mortality, no stroke, and a postproce-
dural hospital stay of 3.9 days in our 27 extremely high-
risk patients, figures that compare very favorably with the
predicted outcomes had standard CABG been used. The
short-term (10.8 months) follow-up results are encourag-
ing, with a 96.3% survival and a 100% freedom from
coronary events in all surviving patients. Length of stay
in the hospital appears to be prolonged if major problems
occur after the operation with any organ system. Multiple
studies have used length of stay as a measure of resource
use27; our reduced length of hospital stay is most likely
due to the absence of major organ complications after
MICABG. Stroke after CABG is a devastating complica-
tion.28 The reported overall incidence of stroke for stan-
dard CABG ranges widely from 0.8% to 3.2% in retro-
spective studies and from 1.5% to 5.2% in prospective
studies.29 The mortality rate from stroke in patients who
have had CABG ranges from 0% to 38%. In a recent
study, stroke dramatically increased the mean hospital
stay from 8.7 days to 25.2 days. The mortality rate for
patients having a stroke was 19.2% compared with 4.2%
of the overall study population.29 Arom and associates30
reported a 12% incidence after MICABG; they relied on
pharmacologic bradycardia using esmolol and adenosine
boluses to minimize the motion of the beating heart. It is
possible that the drastic reduction in cardiac output dur-
ing pharmacologic bradycardia17 can result in hypoperfu-
sion to the brain and ischemic stroke. The absence of
stroke in our very high-risk patients undergoing
MICABG, even when the predicted incidence by McSPI
was 22%, is most likely due to the careful avoidance of
pharmacologic bradycardia, maintenance of high mean
arterial pressure (>80 mm Hg) throughout the operation,
and optimal arterial oxygen saturation.
A limitation of the formal comparisons of observed-
to-expected rates of events and hospital stay is that rel-
atively few of the patients in the CABG cohorts used to
calculate rate estimates were high risk. As a result, the
variability of the estimated outcomes for our small
group of patients having MICABG is quite high. The
highly significant P values in this report must therefore
be regarded as approximate, because they do not rigor-
ously take this variability into account. Our primary
goal in this report, however, is to point out the extremely
low event rates and short hospital stay associated with
MICABG, rather than to carry out a formal statistical
comparison or quantify the expected reduction of risk. 
In conclusion, MICABG, isolated or integrated with
percutaneous intervention, improves outcome in ex-
tremely high-risk patients requiring coronary revascu-
larization and does not correlate with the expected out-
come based on risk assessment models geared for
standard CABG. Despite the small size of our patient
population, we suggest that MICABG has the potential
to expand the benefit of surgical coronary revascular-
ization to patients with otherwise inoperable heart dis-
ease. Long-term follow-up of these clinical results is
therefore warranted.
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